JP2006523224A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006523224A5 JP2006523224A5 JP2006508920A JP2006508920A JP2006523224A5 JP 2006523224 A5 JP2006523224 A5 JP 2006523224A5 JP 2006508920 A JP2006508920 A JP 2006508920A JP 2006508920 A JP2006508920 A JP 2006508920A JP 2006523224 A5 JP2006523224 A5 JP 2006523224A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- composition
- vsv
- dna plasmid
- cytokine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000427 antigen Substances 0.000 claims 22
- 102000036639 antigens Human genes 0.000 claims 22
- 108091007433 antigens Proteins 0.000 claims 22
- 108020004414 DNA Proteins 0.000 claims 19
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 19
- 239000013612 plasmid Substances 0.000 claims 19
- 102000004127 Cytokines Human genes 0.000 claims 11
- 108090000695 Cytokines Proteins 0.000 claims 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 10
- 230000001105 regulatory effect Effects 0.000 claims 9
- 150000007523 nucleic acids Chemical group 0.000 claims 6
- 108091026890 Coding region Proteins 0.000 claims 5
- 230000002163 immunogen Effects 0.000 claims 5
- 230000028993 immune response Effects 0.000 claims 4
- 108091006027 G proteins Proteins 0.000 claims 3
- 102000030782 GTP binding Human genes 0.000 claims 3
- 108091000058 GTP-Binding Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000713311 Simian immunodeficiency virus Species 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 230000005875 antibody response Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45787603P | 2003-03-26 | 2003-03-26 | |
| US54673304P | 2004-02-23 | 2004-02-23 | |
| PCT/US2004/006089 WO2004093906A1 (en) | 2003-03-26 | 2004-03-23 | Immunogenic composition and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011154426A Division JP5635950B2 (ja) | 2003-03-26 | 2011-07-13 | 免疫原性組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006523224A JP2006523224A (ja) | 2006-10-12 |
| JP2006523224A5 true JP2006523224A5 (enExample) | 2007-05-24 |
Family
ID=42828775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006508920A Withdrawn JP2006523224A (ja) | 2003-03-26 | 2004-03-23 | 免疫原性組成物および方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20070134200A1 (enExample) |
| EP (1) | EP1605971B1 (enExample) |
| JP (1) | JP2006523224A (enExample) |
| CN (1) | CN1764474B (enExample) |
| AT (1) | ATE468859T1 (enExample) |
| AU (1) | AU2004231464B2 (enExample) |
| BR (1) | BRPI0408779A (enExample) |
| CA (1) | CA2517010C (enExample) |
| DK (1) | DK1605971T3 (enExample) |
| MX (1) | MXPA05008526A (enExample) |
| NZ (1) | NZ542652A (enExample) |
| PL (1) | PL1605971T3 (enExample) |
| WO (1) | WO2004093906A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| CN102085377B (zh) * | 2003-03-26 | 2014-03-12 | 惠氏公司 | 免疫原性组合物及方法 |
| TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
| DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004033670A1 (de) | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| EP1630163A1 (de) | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004058337A1 (de) | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
| WO2006110344A1 (en) * | 2005-04-07 | 2006-10-19 | Wyeth | Novel methods for inducing an immune response against human immunodefiency virus |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| EP2185559A1 (en) | 2007-08-03 | 2010-05-19 | Boehringer Ingelheim International GmbH | Crystalline form of a dihydropteridione derivative |
| ES2533345T3 (es) * | 2009-06-08 | 2015-04-09 | The University Of Western Ontario | Diferentes serotipos del virus de la estomatitis vesicular como vectores de expresión para regímenes de inmunización |
| ES2625660T3 (es) * | 2009-09-29 | 2017-07-20 | The Trustees Of The University Of Pennsylvania | Método para diagnosticar y tratar encefalitis o epilepsia |
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| HUE043473T4 (hu) | 2010-12-22 | 2019-12-30 | Bayer Ip Gmbh | Fokozott immunválasz szarvasmarha fajokban |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| JP2016525532A (ja) | 2013-07-26 | 2016-08-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 骨髄異形成症候群の処置 |
| JP6772065B2 (ja) | 2014-02-28 | 2020-10-21 | バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｇｍｂｈ | 免疫賦活プラスミド |
| EP3113795B1 (en) | 2014-03-01 | 2019-07-10 | The Board of Regents of The University of Texas System | Recombinant isfahan viral vectors |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
| AU2016302436B2 (en) | 2015-07-31 | 2022-03-03 | Elanco Animal Health Gmbh | Enhanced immune response in porcine species |
| CN105567646B (zh) * | 2016-02-22 | 2019-01-01 | 浙江大学 | 分泌抗甘蔗花叶病毒单抗杂交瘤细胞株及其单抗应用 |
| CN113968907B (zh) * | 2020-07-22 | 2023-05-26 | 中国人民解放军军事科学院军事医学研究院 | 具有中和活性的抗尼帕病毒单克隆抗体及应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE53176B1 (en) * | 1978-12-22 | 1988-08-17 | Biogen Nv | Recombinant dna molecules and their method of production |
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US7153510B1 (en) * | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| AU2001254561A1 (en) * | 2000-04-27 | 2001-11-12 | Aventis Pasteur Limited | Immunizing against hiv infection |
| WO2002097091A1 (en) * | 2001-05-29 | 2002-12-05 | University Of Miami | Generation of hcv-like particles and chimeric hcv virus |
| JP2004537305A (ja) * | 2001-07-11 | 2004-12-16 | ユニバーシティー オブ マイアミ | 腫瘍細胞の処置のための組換えｖｓｖ |
-
2004
- 2004-03-23 JP JP2006508920A patent/JP2006523224A/ja not_active Withdrawn
- 2004-03-23 PL PL04722764T patent/PL1605971T3/pl unknown
- 2004-03-23 WO PCT/US2004/006089 patent/WO2004093906A1/en not_active Ceased
- 2004-03-23 CN CN2004800078180A patent/CN1764474B/zh not_active Expired - Lifetime
- 2004-03-23 EP EP04722764A patent/EP1605971B1/en not_active Expired - Lifetime
- 2004-03-23 MX MXPA05008526A patent/MXPA05008526A/es active IP Right Grant
- 2004-03-23 CA CA2517010A patent/CA2517010C/en not_active Expired - Lifetime
- 2004-03-23 US US10/550,313 patent/US20070134200A1/en not_active Abandoned
- 2004-03-23 NZ NZ542652A patent/NZ542652A/en unknown
- 2004-03-23 BR BRPI0408779-8A patent/BRPI0408779A/pt not_active Application Discontinuation
- 2004-03-23 AT AT04722764T patent/ATE468859T1/de active
- 2004-03-23 DK DK04722764.0T patent/DK1605971T3/da active
- 2004-03-23 AU AU2004231464A patent/AU2004231464B2/en not_active Expired
-
2012
- 2012-04-24 US US13/454,884 patent/US20120244113A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006523224A5 (enExample) | ||
| Kalams et al. | Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults | |
| Kent et al. | Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus | |
| Goepfert et al. | Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles | |
| Earl et al. | Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140 | |
| Fuchs et al. | First-in-human evaluation of the safety and immunogenicity of a recombinant vesicular stomatitis virus human immunodeficiency virus-1 gag vaccine (HVTN 090) | |
| Bansal et al. | Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration | |
| Barouch et al. | Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys | |
| Mpendo et al. | A phase I double blind, placebo-controlled, randomized study of the safety and immunogenicity of electroporated HIV DNA with or without interleukin 12 in prime-boost combinations with an Ad35 HIV vaccine in healthy HIV-seronegative African adults | |
| Wu et al. | Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens | |
| Vaccari et al. | Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV | |
| Nilsson et al. | HIV-DNA given with or without intradermal electroporation is safe and highly immunogenic in healthy Swedish HIV-1 DNA/MVA vaccinees: a phase I randomized trial | |
| JP2003534016A (ja) | 天然ウイルス感染を模倣し、病原体に対する持続的な免疫を誘発する遺伝子ワクチン | |
| Li et al. | DNA priming increases frequency of T-cell responses to a vesicular stomatitis virus HIV vaccine with specific enhancement of CD8+ T-cell responses by interleukin-12 plasmid DNA | |
| Hartnell et al. | A novel vaccine strategy employing serologically different chimpanzee adenoviral vectors for the prevention of HIV-1 and HCV coinfection | |
| JP2006523224A (ja) | 免疫原性組成物および方法 | |
| Voss et al. | Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine | |
| Spearman | HIV vaccine development: lessons from the past and promise for the future | |
| Goepfert et al. | High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects | |
| Ake et al. | Safety and immunogenicity of PENNVAX-G DNA prime administered by Biojector 2000 or CELLECTRA electroporation device with modified vaccinia Ankara-CMDR boost | |
| Nilsson et al. | Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees | |
| CA2419822A1 (en) | Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization | |
| Berkley et al. | Scientific and policy challenges to development of an AIDS vaccine | |
| JP2013507107A5 (enExample) | ||
| Perdiguero et al. | Heterologous combination of VSV-GP and NYVAC vectors expressing HIV-1 trimeric gp145 Env as vaccination strategy to induce balanced B and T cell immune responses |